De Vries Raymond Gene, Tomlinson Tom, Kim Hyungjin Myra, Krenz Chris, Haggerty Diana, Ryan Kerry A, Kim Scott Y H
Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan, United States of America.
Center for Ethics and Humanities in the Life Sciences, Michigan State University, East Lansing, Michigan, United States of America.
PLoS One. 2016 Jul 14;11(7):e0159113. doi: 10.1371/journal.pone.0159113. eCollection 2016.
Researchers and policymakers do not agree about the most appropriate way to get consent for the use of donations to a biobank. The most commonly used method is blanket-or broad-consent where donors allow their donation to be used for any future research approved by the biobank. This approach does not account for the fact that some donors may have moral concerns about the uses of their biospecimens. This problem can be avoided using "real-time"-or study-by-study-consent, but this policy places a significant burden on biobanks. In order to better understand the public's preferences regarding biobank consent policy, we surveyed a sample that was representative of the population of the United States. Respondents were presented with 5 biobank consent policies and were asked to indicate which policies were acceptable/unacceptable and to identify the best/worst policies. They were also given 7 research scenarios that could create moral concern (e.g. research intending to make abortions safer and more effective) and asked how likely they would be to provide broad consent knowing that their donation might be used in that research. Substantial minorities found both broad and study-by-study consent to be unacceptable and identified those two options as the worst policies. Furthermore, while the type of moral concern (e.g., regarding abortion, the commercial use of donations, or stem cell research) had no effect on policy preferences, an increase in the number of research scenarios generating moral concerns was related to an increased likelihood of finding broad consent to be the worst policy. The rejection of these ethically problematic and costly extremes is good news for biobanks. The challenge now is to design a policy that combines consent with access to information in a way that assures potential donors that their interests and moral concerns are being respected.
研究人员和政策制定者对于获取生物样本库捐赠使用同意书的最合适方式存在分歧。最常用的方法是全面同意或广泛同意,即捐赠者允许其捐赠用于生物样本库批准的任何未来研究。这种方法没有考虑到一些捐赠者可能对其生物样本的使用存在道德顾虑这一事实。使用“实时”同意或逐研究同意可以避免这个问题,但这种政策给生物样本库带来了巨大负担。为了更好地了解公众对生物样本库同意政策的偏好,我们对具有美国人口代表性的样本进行了调查。受访者看到了5种生物样本库同意政策,并被要求指出哪些政策是可接受的/不可接受的,并确定最佳/最差政策。他们还看到了7种可能引发道德顾虑的研究场景(例如,旨在使堕胎更安全、更有效的研究),并被问及在知道自己的捐赠可能用于该研究的情况下,他们提供广泛同意的可能性有多大。相当一部分少数群体认为全面同意和逐研究同意都是不可接受的,并将这两种选择列为最差政策。此外,虽然道德顾虑的类型(例如,关于堕胎、捐赠的商业用途或干细胞研究)对政策偏好没有影响,但引发道德顾虑的研究场景数量增加与认为全面同意是最差政策的可能性增加有关。拒绝这些存在伦理问题且成本高昂的极端做法对生物样本库来说是个好消息。现在的挑战是设计一种政策,将同意与信息获取结合起来,以确保潜在捐赠者相信他们的利益和道德顾虑得到了尊重。